Vir Biotechnology (VIR) Stock Price & Analysis

VIR$9.96-2.16 -17.82%
BiotechnologyGrowth Stock
Compare
Market cap$1.71BEnterprise value$1.85BRevenue (TTM)$302.80MMarket position—

Score

64
Neutral
Value
46
Quality
46
Growth
100

AI Analysis

Snapshot

Vir Biotechnology is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 64/100) in Biotechnology. Under the hood: revenue compounding ~-39% annually over recent years. Street targets still imply ~136% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

46
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

46
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Vir Biotechnology, Inc. (VIR) last printed $9.96. Equity value is $1.71B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

201720182019202020212022202320242025
$2.71M$10.67M$8.09M$76.37M$1.1B$1.62B$86.18M$74.2M$68.56M

About

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.

Vir Biotechnology (VIR) Stock Price & Analysis

VIR price $9.96 -2.16 -17.82%

Ticker
VIR
Price
$9.96
Change
-2.16 -17.82%
Market cap
$1.71B
Dividend yield
0.00%
Beta
1.70
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
64
Value
46
Quality
46
Growth
100

Stocklytics score rationale: value 46, quality 46, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener